The effects of add-on exenatide to insulin on glycemic variability and hypoglycemia in patients with type 1 diabetes mellitus

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Journal of Endocrinological Investigation

• Publication date

  2018-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s40618-017-0765-0PMID 29032494
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Glucagon-like peptide-1 receptor agonists and atrial fibrillation: a systematic review and meta-analysis of randomised controlled trials

  2017cited by this paper
• Effects of sitagliptin on counter‐regulatory and incretin hormones during acute hypoglycaemia in patients with type 1 diabetes: a randomized double‐blind placebo‐controlled crossover study

  2015cited by this paper
• Counter‐regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo‐controlled, double‐blind, crossover trial

  2015cited by this paper
• Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy.

  2014cited by this paper
• Insulin secretion measured by stimulated C‐peptide in long‐established Type 1 diabetes in the Diabetes Control and Complications Trial (DCCT)/ Epidemiology of Diabetes Interventions and Complications (EDIC) cohort: a pilot study

  2014cited by this paper
• Effect of sitagliptin therapy on triglyceride‐rich lipoprotein kinetics in patients with type 2 diabetes

  2014cited by this paper
• Absence of Glucagon and Insulin Action Reveals a Role for the GLP-1 Receptor in Endogenous Glucose Production

  2014cited by this paper
• Exenatide Treatment for 6 Months Improves Insulin Sensitivity in Adults With Type 1 Diabetes

  2014cited by this paper
• Glucagon Response to Oral Glucose Challenge in Type 1 Diabetes: Lack of Impact of Euglycemia

  2014cited by this paper
• Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus.

  2013cited by this paper
• Lack of Association Between Residual Insulin Production and Glucagon Response to Hypoglycemia in Youth With Short Duration of Type 1 Diabetes

  2013cited by this paper
• Acute Metabolic Effects of Exenatide in Patients With Type 1 Diabetes With and Without Residual Insulin to Oral and Intravenous Glucose Challenges

  2013cited by this paper
• The effects of dipeptidyl peptidase-4 inhibitors in treatment of obese patients with type 2 diabetes.

  2013cited by this paper
• Most Youth With Type 1 Diabetes in the T1D Exchange Clinic Registry Do Not Meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes Clinical Guidelines

  2013cited by this paper
• AACE comprehensive diabetes management algorithm 2013.

  2013cited by this paper
• Glucose‐lowering effect of the DPP‐4 inhibitor sitagliptin after glucose and non‐glucose macronutrient ingestion in non‐diabetic subjects

  2013cited by this paper
• Early Loss of the Glucagon Response to Hypoglycemia in Adolescents With Type 1 Diabetes

  2012cited by this paper
• Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes.

  2012cited by this paper
• Direct effect of GLP-1 infusion on endogenous glucose production in humans

  2012cited by this paper
• Liraglutide as additional treatment for type 1 diabetes.

  2011cited by this paper
• Continued Reduction in the Prevalence of Retinopathy in Adolescents With Type 1 Diabetes

  2011cited by this paper
• Oxidative stress and diabetic complications.

  2010cited by this paper
• Effect of glucagon-like peptide-1 on alpha- and beta-cell function in C-peptide-negative type 1 diabetic patients.

  2010cited by this paper
• Oxidative stress and beta-cell dysfunction

  2010cited by this paper
• Hypoglycemia: still the limiting factor in the glycemic management of diabetes.

  2008cited by this paper
• Insulin‐associated weight gain in diabetes – causes, effects and coping strategies

  2007cited by this paper
• Insulin secretion-independent effects of GLP-1 on canine liver glucose metabolism do not involve portal vein GLP-1 receptors.

  2005cited by this paper
• Effects of glucagon-like peptide 1 on the hepatic glucose metabolism.

  2004cited by this paper
• Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes.

  2004cited by this paper
• Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation

  1998cited by this paper
• Use of a heated superficial hand vein as an alternative site for the measurement of amino acid concentrations and for the study of glucose and alanine kinetics in man.

  1981cited by this paper

• Efficacy and safety of GLP-1 receptor agonists and SGLT2 inhibitors as adjuncts to insulin in type 1 diabetes: Systematic review and meta-analysis.

  2026cites this paper
• Differences in the insulin counterregulatory hormones between obese and nonobese male patients with type 2 diabetes mellitus

  2025influential citation
• Comparative Evaluation of Responsiveness of Insulin Counter-Regulatory Hormones and Insulin Resistance to Hypoglycemia in Newly Diagnosed Type 1 Diabetes Mellitus Man

  2025cites this paper
• Incretin‐Based Adjunct to Background Insulin Treatment for Managing Body Weight Excess in Type 1 Diabetes: An Expert Opinion Viewpoint From the Italian Association of Clinical Endocrinologists

  2025cites this paper
• Effect of Glucagon‐Like Peptide‐1 Receptor Agonists on Cardiometabolic Risk Factors in Type 1 Diabetes Mellitus: A Systematic Review and Meta‐Analysis

  2025cites this paper
• Effects of glucagon‐like peptide‐1 receptor agonists on glycated haemoglobin and continuous glucose monitoring metrics as adjunctive therapy to insulin in adults with type 1 diabetes: A meta‐analysis of randomized controlled trials

  2024cites this paper
• Mechanistic Pathways and Clinical Implications of GLP-1 Receptor Agonists in Type 1 Diabetes Management

  2024cites this paper
• Can Unmet Needs Be Addressed by Adjunctive Therapies? Findings from a Patient Perspectives Survey in Adults with Type 1 Diabetes

  2024cites this paper
• Incretins beyond type 2 diabetes

  2023cites this paper
• Sex Hormone Binding Globulin is an Independent Predictor for Insulin Resistance in Male Patients with Newly Diagnosed Type 2 Diabetes Mellitus

  2023cites this paper
• Glucagon-like peptide 1 Analogues as Adjunctive Therapy for Patients with Type 1 Diabetes: an Updated Systematic Review and Meta-analysis.

  2023cites this paper
• Recent developments in adjunct therapies for type 1 diabetes

  2022cites this paper
• Glucose-Lowering Therapy beyond Insulin in Type 1 Diabetes: A Narrative Review on Existing Evidence from Randomized Controlled Trials and Clinical Perspective

  2022cites this paper
• hUCMSCs carrying exenatide prevent T1DM by improving intestinal microflora composition and islet tissue damage repair

  2022cites this paper
• DMSO_A_343514 4865..4873

  2021cites this paper
• Obesity in Patients with Type 1 Diabetes: Links, Risks and Management Challenges

  2021cites this paper
• The Role of Glucagon in Glycemic Variability in Type 1 Diabetes: A Narrative Review

  2021cites this paper
• DMSO_A_223618 2807..2827

  2021cites this paper
• Glycemic Variability Impacted by SGLT2 Inhibitors and GLP 1 Agonists in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis

  2021cites this paper
• The impact of pharmacological and lifestyle interventions on body weight in people with type 1 diabetes: A systematic review and meta‐analysis

  2020cites this paper
• Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial.

  2020cites this paper
• Effect of short-acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double-blind placebo-controlled trial.

  2020cites this paper
• Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial

  2018cites this paper
• Clinical and basic studies of GLP-1 receptor agonists for the treatment of diabetes in China

  2018cites this paper
• World Journal of Diabetes

  year unknowncites this paper